Clinical Trials Available

A4 Study: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee L. Pierce, MD

Location:

UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Newport Diagnostic Center, CARE Clinic in Laguna Woods)

Purpose:

To evaluate whether immunization treatment with solanezumab versus placebo will slow cognitive decline in individuals showing the presence of elevated protein called amyloid on a brain scan.

Eligibility:

Male and female participants, ages 65-85 years old, with evidence of elevated brain amyloid pathology on a brain scan.

Time Commitment:

Screening phase (up to 90 days) and treatment phase (48 visits over the course of 168 weeks or ~3 years)

Benefits:

You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug, solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed.

The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.

Compensation:

Participants are eligible to receive the following compensation in cash during the course of this study:

  • $100 for each completed MRI scan; there are 4 MRI scans ($400 max).
  • $100 for each completed PET scan; there are 2 PET scans ($200 max).
  • $100 for each completed lumbar puncture; there are two optional lumbar punctures ($200 max).
  • $50 for each infusion visit requiring infusion; there are 42 infusion visits in this study ($2100 max).

The grand total compensation for this study is a maximum of $2900 in cash.

Participants will also be reimbursed $40 in cash for travel-related expenses for each visit required for the study.

Contact Name: Beatriz Yanez, RN

Phone: 949-824-3250

Email: byanez@uci.edu

Study website: http://a4study.org/

 

INI Study: SNIFF –The Study Of Nasal Insulin To Fight Forgetfulness

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee L. Pierce, MD

Location:

UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Newport Diagnostic Center)

Purpose:

To evaluate whether insulin, when administered as a nasal spray, improves memory in adults amnesiac mild cognitive impairment (aMCI) or early Alzheimer’s disease (AD).

Eligibility:

Male and female participants, ages 55-85 years old and diagnosed with aMCI or AD

Time Commitment:

18 months total: treatment phase (twice daily intake of nasal insulin or placebo for 12 months), open label phase (twice daily intake of nasal insulin for 6 months)

Benefits:

There is no guarantee of personal benefit from participating in this research study.  All subjects will receive active study drug for a period of 6 months during the open label phase.  Subjects will also receive their blood test results which may reveal more information about their blood sugar, cholesterol, liver function and other related health information.

Compensation:

Participants are eligible to receive the following compensation in cash during the course of this study:

  • $25 for each study visit; there are 8 visits ($200 max).
  • $100 for each completed lumbar puncture; there are two lumbar punctures ($200 max).

The grand total compensation for this study is a maximum of $400 in cash.

Phone: 949-824-6187

Contact the Clinical Trials Team

For more information about available or upcoming studies, please contact the Clinical Trials team.

Telephone: (949) 824-3250 or (949) 824-5733
Email: byanez@uci.edu

 


 

Donate